 The U.S. Food and Drug Administration (FDA) granted the application for fenfluramine priority review and orphan drug designations.The FDA granted approval of Fintepla to Zogenix, Inc.

Fenfluramine was formerly marketed under the brand names Pondimin, Ponderax, and Adifax, among others.Unlike various other amphetamine derivatives, fenfluramine is reported to be dysphoric, "unpleasantly lethargic", and non-addictive at therapeutic doses.